Catalyst4 Boosts MapLight Stake with $83.4M Open-Market Purchase
MPLT sits 27% above its 52-week low of $9.1.
Summary
Catalyst4, Inc. purchased $83.4 million of MapLight Therapeutics stock and warrants on August 14, 2026, increasing its stake to 25.3 million shares.
Key Events · Ownership and Investor Activity · MPLT
-
Catalyst4 Purchases $83.4M of MapLight Securities
Catalyst4, Inc. acquired 4,400,000 shares of common stock at $11.38 per share and 2,928,686 warrants at $11.3799 per warrant on August 14, 2026, totaling $83,400,154.
-
Ownership Increases to 25.3 Million Shares
Post-transaction, Catalyst4 holds 25,306,689 shares of MapLight Therapeutics, representing a significant increase from its prior stake.
-
Warrants Exercisable but Capped at 49.99%
The 2,928,686 warrants are immediately exercisable at $0.0001 per share but cannot be exercised if Catalyst4's beneficial ownership would exceed 49.99%.
-
Follows $15.3M July Purchase and $150M Private Placement
This purchase follows Catalyst4's $15.3 million open-market purchase in late July and MapLight's $150 million private placement announced August 13, 2026.
Analysis · MPLT · Life Sciences
Catalyst4, Inc., a 10% owner of MapLight Therapeutics, purchased $83.4 million of stock and warrants on August 14, 2026, at $11.38 per share. This follows a $15.3 million purchase in late July and a $150 million private placement announced August 13. The purchase increases Catalyst4's ownership to 25.3 million shares, reinforcing its position as the largest shareholder. The warrants are immediately exercisable but capped at 49.99% ownership, limiting further dilution. This accumulation signals strong conviction in MapLight's pipeline despite recent mixed clinical trial results.
At the time of this filing, MPLT was trading at $11.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $503.7M. The 52-week trading range was $9.10 to $40.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.